Clinical trials: Statin Therapy
Hypercholesteremia
Direct Statin Comparison of LDL-C Values: an Evaluation of Rosuvastatin Therapy
The primary objective of the study is to compare the efficacy of rosuvastatin 10 mg with atorvastatin 10 mg by assessment of the percentage of subjects who reach EAS LDL-C target goals after 12 weeks of therapy.
- Trial name
- NCT00239330
- Testing
- Rosuvastatin, Atorvastatin
- Where
- 26 sites in Belgium
- Volunteers
- 824 people
- Sponsor
- AstraZeneca
Hypercholesterolemia
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021)
This study will evaluate the effects of 2 different dose levels of anacetrapib on low-density lipoprotein-cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) in participants with hypercholesterolemia when added…
- Trial name
- NCT01717300
- Testing
- Anacetrapib 100 mg, Anacetrapib 25 mg
- Volunteers
- 459 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypercholesterolemia
Pharmacokinetics of Butyrate Tablet BKR-017
The purpose of this study is to evaluate the pharmacokinetic profile and systemic exposure of BKR-017 in individuals on statin therapy after a single dose and at steady state after seven days repeated twice daily dosing.
- Trial name
- NCT06556745
- Testing
- BKR-017
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- BioKier Inc.
Dyslipidemia/Glucose Metabolism Disorder
Fenofibrate and Metformin Fixed Combination vs Metformin - FAME METFO
To demonstrate in patients with T2DM and dyslipidemia not appropriately controlled with a statin and receiving metformin, the superiority of a fixed combination of fenofibrate and metformin vs metformin alone on TG and…
- Trial name
- NCT00362323
- Testing
- fenofibrate (F) + metformin (M) hydrochloride fixed combination, Metformin
- Where
- 70 sites in Czechia, France and 5 more
- Volunteers
- 482 people
- Sponsor
- Solvay Pharmaceuticals
STEMI, Dyslipidemias
The Safety and Long-Term Clinical Benefit of PCSK9i in STEMI Patients
Patients with acute coronary syndromes (ACS) have an increased risk of recurrent ischemic events, particularly during the first year following the index event, which is mainly due to unattended risk factors and/ or poor…
- Trial name
- NCT05579418
- Testing
- Evolocumab
- Volunteers
- 350 people
- Sponsor
- Hamad Medical Corporation
Carotid Atherosclerosis
Merck Carotid Atherosclerosis Trial (MK-0000-111)(COMPLETED)
This study will examine the effect of statin and niacin therapy on carotid plaque biomarkers
- Trial name
- MCAT (NCT00804843)
- Testing
- Atorvastatin/niacin extended-release, Atorvastatin, Simvastatin
- Volunteers
- 100 people
- Sponsor
- Merck Sharp & Dohme LLC
Dyslipidemias, Hypercholesterolemia
Effect of Statins on Lipid Levels Following the First Acute Coronary Event (MK-0000-204)
The current study is proposed to investigate the pattern of dyslipidemia and of lipid treatment practices in patients in India experiencing their first acute cardiovascular event and the extent of residual dyslipidemia after 12…
- Conditions
- Dyslipidemias, Hypercholesterolemia, Hypertriglyceridemia, High LDL-C
- Trial name
- REMAINS (NCT01245738)
- Volunteers
- 635 people
- Sponsor
- Merck Sharp & Dohme LLC
Coronary Disease, Myocardial Infarction
Fluvastatin in the Therapy of Acute Coronary Syndrome
This study is to evaluate the safety and efficacy of fluvastatin versus placebo, dosed shortly after or immediately when the coronary event occurs.
- Trial name
- NCT00171275
- Testing
- Fluvastatin
- Where
- Czechia
- Volunteers
- 1,000 people
- Sponsor
- Novartis
Hypercholesterolemia
Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing Statins in Patients With Primary Hypercholesterolemia
The present study is assessing the efficacy and safety of AVE5530 (25 mg and 50 mg) in add-on to ongoing statin treatment in a double-blind manner in comparison with placebo, in the management of patients with primary…
- Trial name
- NCT00729027
- Testing
- 25 mg/day AVE5530, 50 mg/day AVE5530
- Where
- 16 sites in United States, Australia and 14 more
- Volunteers
- 1,015 people
- Sponsor
- Sanofi
Hypercholesterolemia
Dose-escalating Safety Study in Subjects on Stable Statin Therapy
The aim of this study is to assess the safety of varying doses of ISIS 301012 in subjects on Stable statin therapy.
- Trial name
- NCT00231569
- Where
- 5 sites in United States, Netherlands
- Volunteers
- 74 people
- Sponsor
- Kastle Therapeutics, LLC
Mixed Dyslipidemia
A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia
The objective of the study is to assess the continued safety of the daily coadministration of ABT-335 in combination with rosuvastatin calcium, simvastatin or atorvastatin calcium.
- Trial name
- NCT00491530
- Testing
- ABT-335, rosuvastatin calcium, simvastatin
- Where
- United States
- Volunteers
- 310 people
- Sponsor
- Abbott
Hypercholesteremia
C-Control: Efficacy and Safety of Therapy With Rosuvastatin in Statin-Naive and in Statin-Switched Patients
The study explores efficacy and safety of the lipid-lowering therapy with CRESTOR in statin-naive patients and in patients with previously unsuccessful statin therapy.
- Trial name
- NCT00688454
- Volunteers
- 3,392 people
- Sponsor
- AstraZeneca
Hypercholesterolemia
A Study to Assess the Cholesterol Lowering Effect of an Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Patients With High Cholesterol and With High Cardiovascular Risk (0653A-809)(COMPLETED)
This is a multicenter study to evaluate the safety and efficacy of ezetimibe/simvastatin versus rosuvastatin in participants with high cholesterol.
- Trial name
- NCT00479713
- Testing
- ezetimibe (+) simvastatin, Comparator : rosuvastatin calcium
- Volunteers
- 618 people
- Sponsor
- Organon and Co
Hypercholesterolemia
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4
The primary objective of the study was to evaluate the effect of 12 weeks of subcutaneous (SC) evolocumab compared with ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in…
- Trial name
- GAUSS-4 (NCT02634580)
- Testing
- Evolocumab, Ezetimibe
- Where
- 35 sites in Japan
- Volunteers
- 61 people
- Sponsor
- Amgen
Hypercholesterolemia
Study of an Approved Drug With a Statin (a Medication That Lowers Cholesterol Levels) as Compared to Statin Therapy Alone in Patients With High Cholesterol (0653-040)
The purpose of this 6-week study is to compare the reduction in specific levels of cholesterol in patients with high cholesterol.
- Trial name
- NCT00092586
- Testing
- MK0653, ezetimibe, Comparator: statins
- Volunteers
- 2,904 people
- Sponsor
- Organon and Co
Hypercholesterolemia
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)
Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9).
- Trial name
- NCT01644188
- Testing
- Alirocumab, Ezetimibe, Lipid Modifying Therapy (LMT)
- Where
- 126 sites in United States, Canada and 8 more
- Volunteers
- 720 people
- Sponsor
- Sanofi
Dyslipidemias, Hypercholesterolemia
Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies
The study is a placebo-controlled, double-blind, randomized, phase 3 study in participants with heterozygous familial hypercholesterolemia (HeFH) and/or atherosclerotic cardiovascular disease (ASCVD) or multiple ASCVD risk…
- Conditions
- Dyslipidemias, Hypercholesterolemia, Familial Hypercholesterolemia, ASCVD
- Trial name
- TANDEM (NCT06005597)
- Testing
- Combination Therapy, Monotherapy obicetrapib, Monotherapy ezetimibe
- Where
- 45 sites in United States
- Volunteers
- 407 people
- Sponsor
- NewAmsterdam Pharma
Hyperlipidemia
A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg
The purpose of this research study is to measure the amount of atorvastatin and ETC-1002 in the blood, to determine how ETC-1002 affects the level of LDL-cholesterol (bad cholesterol) and other markers of health and disease in…
- Trial name
- NCT02659397
- Testing
- ETC-1002, Atorvastatin
- Where
- 19 sites in United States
- Volunteers
- 68 people
- Sponsor
- Esperion Therapeutics, Inc.
Atherosclerotic Cardiovascular Disease
A Randomized Study to Evaluate the Effect of an "Inclisiran First" Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE)
The purpose of this study was to assess the effectiveness of an "inclisiran first" implementation strategy (addition of inclisiran to maximally tolerated statin therapy immediately upon failure to achieve acceptable LDL-C with…
- Trial name
- V-INITIATE (NCT04929249)
- Testing
- Inclisiran
- Where
- 43 sites in United States
- Volunteers
- 450 people
- Sponsor
- Novartis Pharmaceuticals
Dyslipidemias, High Cholesterol
Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy
This study will be a placebo-controlled, double-blind, randomized, phase 2 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10 mg, both in combination with ezetimibe 10 mg and as monotherapy, as an adjunct…
- Conditions
- Dyslipidemias, High Cholesterol, Hypercholesterolemia
- Trial name
- ROSE2 (NCT05266586)
- Testing
- Obicetrapib, Ezetimibe 10mg
- Where
- 16 sites in United States
- Volunteers
- 119 people
- Sponsor
- NewAmsterdam Pharma